Hybrid and decentralized clinical trials (DCTs) are fast becoming the norm, but they often involve multiple vendors and service providers, presenting sponsors and CROs with new considerations on the logistics of study conduct. By leveraging the expertise of their vendors, sponsors and contract research organizations (CROs) can avoid common pitfalls that can contribute to inefficiencies, safety concerns, and increased costs.
Read the Drug Discovery World article by Stephanie Larimer, Q2 Solutions, Decentralized Trials Solutions Manager and Tom Brazier, mdgroup, Decentralized Clinical Solutions Director, as they shared their insights and opportunities for decentralized clinical trials and how common pitfalls can be avoided through communications and streamlined working.
Read the article
